
1. j antimicrob chemother. 2011 jan;66(1):180-3. doi: 10.1093/jac/dkq411. epub 2010 
nov 2.

nevirapine pharmacokinetics initiated 200 mg 400 mg daily hiv-1 and
tuberculosis co-infected ugandan adults rifampicin.

lamorde m(1), byakika-kibwika p, okaba-kayom v, ryan m, coakley p, boffito m,
namakula r, kalemeera f, colebunders r, back d, khoo s, merry c.

author information: 
(1)research department, infectious diseases institute, makerere university
college health sciences, kampala, uganda. mlamorde@idi.co.ug

background: rifampicin lowers nevirapine plasma concentrations inducing
cytochrome p450. however, data available interaction the
lead-in period nevirapine treatment.
methods: eighteen hiv-1/tuberculosis co-infected adults receiving rifampicin
daily part anti-tuberculosis therapy evenly randomized nevirapine
initiation dose escalation (nvp200) nevirapine initiation 200 mg twice
daily (nvp400). subjects underwent 12 h intensive pharmacokinetic sampling on
days 7, 14 21 nevirapine treatment. minimum effective concentration
(mec) 3000 ng/ml used interpret nevirapine concentrations 12 h after
dosing (c(12)).
trial registration number: nct00617643 (www.clinicaltrials.gov).
results: day 7 geometric mean nevirapine c(12) [90% confidence interval (ci)] was
1504 (1127-2115) ng/ml 3148 (2451-4687) ng/ml nvp200 nvp400 arms, 
respectively (p < 0.01). nevirapine c(12) days 14 21 similar. day
21, nevirapine concentration 64% patients mec. day 7,
geometric mean area curve (auc(0-12)) lower nvp200 arm,
25 223 (90% ci, 21 978-29 695) ng·h/ml versus 43 195 (35 607-57 035) ng·h/ml in
the nvp400 arm (p  <  0.01). similarly, day 14, nevirapine auc(0-12) lower
in nvp200 arm 23 668 (18 253-32 218) ng·h/ml versus nvp400 arm 44 918
(36 264-62 769) ng·h/ml (p = 0.03).
conclusions: co-treated patients, nevirapine concentrations mec
during initiation dose escalation. nevirapine initiation maintenance 
dose 200 mg twice daily preferred. sub-therapeutic nevirapine
concentrations common day 21 either regimen. evaluation higher
nevirapine maintenance doses may considered.

doi: 10.1093/jac/dkq411 
pmcid: pmc3001850
pmid: 21047828  [indexed medline]

